UMA Drops 10.73% in 24 Hours Amidst Kyowa Kirin's Announcement to Take Full Control of Rocatinlimab Development

On JAN 31 2026, UMA dropped by 10.73% within 24 hours to reach $0.566, UMA dropped by 17.61% within 7 days, dropped by 19.26% within 1 month, and dropped by 19.26% within 1 year. Kyowa Kirin announced it had ended its collaboration with Amgen and would now take full control of the development and commercialization of Rocatinlimab, a potential therapy for moderate-to-severe atopic dermatitis. The move follows positive Phase 3 trial results and a strategic decision by Amgen to prioritize its portfolio. Kyowa Kirin expressed confidence in the drug's potential as a long-term treatment option and plans to submit regulatory applications in the first half of 2026.